scPharmaceuticals (SCPH) AI Stock Analysis

• Market Cap: $302.21M
• Dividend Yield: N/A
• Average Volume (3M): 1.90M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.38
• Revenue Growth: 107.79%
• EPS Growth: -16.01%
• Country: US
• Employees: 162
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.34
• Shares Outstanding: 53,678,800
• 10 Day Avg. Volume: 1,023,532
• 30 Day Avg. Volume: 1,902,935
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.72
• Enterprise Value/Revenue: 4.33
• Enterprise Value/Gross Profit: 6.32
• Enterprise Value/Ebitda: -2.62
• 1Y Price Target: $11.84
• Price Target Upside: 109.56% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5

• Rating: 59 Neutral
• Price Target: $6.00 ▲(6.19% Upside)

scPharmaceuticals' overall stock score is primarily impacted by its financial instability, with high debt levels and negative cash flows posing significant risks. However, strong technical indicators and positive strategic developments, such as the merger with MannKind Corporation, provide a counterbalance, suggesting potential for future growth. The earnings call further supports optimism with robust revenue growth and strategic advancements, despite ongoing cost challenges.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong market demand and successful product adoption, enhancing long-term financial prospects.

Strategic Merger

The merger with MannKind is expected to expand market reach and integrate commercial capabilities, potentially accelerating revenue growth.

Product Innovation

The new auto-injector could significantly reduce treatment time, enhancing patient convenience and increasing market penetration.

Negative Factors

High Debt Levels

High debt levels can strain financial resources and limit flexibility, posing risks to long-term stability and growth potential.

Negative Cash Flow

Negative cash flow indicates cash outflows exceed inflows, potentially impacting the ability to fund operations and growth sustainably.

Profitability Challenges

Ongoing profitability challenges highlight difficulties in achieving operational efficiency, affecting long-term financial health.

scPharmaceuticals Business Overview & Revenue Model

Company Description

scPharmaceuticals Inc. is a biotechnology company focused on the development and commercialization of innovative pharmaceutical products that utilize its proprietary subcutaneous drug delivery technology. The company operates primarily in the healthcare sector, with a core focus on providing treatments for patients with chronic conditions, particularly in the areas of heart failure and other serious illnesses. scPharmaceuticals aims to enhance patient outcomes and improve the convenience of administering medications through its products, which include its lead product candidate, Furoscix, a subcutaneous formulation of furosemide for the treatment of worsening heart failure.

How the Company Makes Money

scPharmaceuticals generates revenue primarily through the commercialization of its pharmaceutical products, particularly Furoscix, once it receives regulatory approval. The company's revenue model includes direct sales of its products to healthcare providers and patients. Additionally, scPharmaceuticals may engage in partnerships and collaborations with other pharmaceutical companies or healthcare organizations, which can provide upfront payments, milestone payments, and royalties based on product sales. These strategic partnerships can enhance the company's financial stability and expand its market reach. The company may also explore licensing agreements that allow other entities to develop or market its products, further contributing to its revenue streams.

scPharmaceuticals Financial Statement Overview

Summary

scPharmaceuticals shows promising revenue growth, yet faces significant challenges in profitability, leverage, and cash flow. The company's high debt levels and negative equity position indicate financial instability, while negative cash flows suggest ongoing operational difficulties. Continued focus on improving operational efficiency and financial health is essential for future stability and growth.

Income Statement

The company demonstrated a significant increase in revenue from 2023 to 2024, showing positive growth potential. However, profitability remains a concern, with consistent net losses and negative EBIT and EBITDA margins, indicating challenges in achieving operational efficiency and profitability.

Balance Sheet

The balance sheet reflects a high debt-to-equity ratio, indicating significant leverage and potential financial risk. Negative stockholders' equity is a concern, suggesting liabilities exceed assets, which may pose financial stability risks. The equity ratio is negative, highlighting the company's reliance on debt financing.

Cash Flow

Operating cash flow remains negative, reflecting ongoing operational challenges. Free cash flow is also negative, indicating cash outflows exceed cash inflows, which may impact the company's ability to fund operations and growth without external financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	49.97M	36.33M	13.59M	0.00	0.00	0.00
Gross Profit	34.21M	24.97M	9.78M	-468.00K	-438.00K	-399.00K
EBITDA	-82.60M	-77.43M	-46.06M	-33.07M	-25.02M	-29.22M
Net Income	-91.72M	-85.15M	-54.81M	-36.84M	-28.03M	-32.21M
Balance Sheet
Total Assets	80.25M	107.52M	94.48M	124.19M	79.04M	109.05M
Cash, Cash Equivalents and Short-Term Investments	40.81M	75.66M	76.01M	118.37M	75.46M	105.28M
Total Debt	52.45M	52.69M	40.27M	37.37M	17.64M	20.21M
Total Liabilities	101.57M	94.20M	57.26M	51.76M	22.57M	26.88M
Stockholders Equity	-21.32M	13.32M	37.22M	72.43M	56.47M	82.17M
Cash Flow
Free Cash Flow	-65.88M	-70.56M	-59.28M	-34.60M	-27.16M	-27.69M
Operating Cash Flow	-65.86M	-70.54M	-59.24M	-34.58M	-27.15M	-27.69M
Investing Cash Flow	-21.00K	29.30M	19.96M	-45.86M	32.13M	-33.46M
Financing Cash Flow	68.19M	70.08M	14.85M	77.23M	-2.53M	60.35M

scPharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.65
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCPH, the sentiment is Positive. The current price of 5.65 is above the 20-day moving average (MA) of 5.60, above the 50-day MA of 5.31, and above the 200-day MA of 3.79, indicating a bullish trend. The MACD of 0.13 indicates Positive momentum. The RSI at 63.73 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SCPH.

scPharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SCPH	59 Neutral	$302.21M	―	-934.02%	―	107.79%	-16.01%
TNXP	57 Neutral	212.22M	-0.02	-93.18%	―	-21.09%	90.95%
NKTR	56 Neutral	1.11B	-6.71	505.02%	―	-19.56%	35.55%
LRMR	49 Neutral	436.08M	-3.26	―	―	―	-40.03%
KOD	35 Underperform	834.58M	-4.17	―	―	―	-0.69%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

scPharmaceuticals Corporate Events

scPharmaceuticals Announces Merger with MannKind Corporation

On August 24, 2025, scPharmaceuticals entered into a merger agreement with MannKind Corporation, which will acquire all outstanding shares of scPharmaceuticals through a tender offer. The acquisition, valued at up to $360 million, aims to diversify and accelerate MannKind’s revenue growth, particularly with FUROSCIX, and strengthen its position in the cardiometabolic and lung disease sectors. The merger is expected to close in the fourth quarter of 2025, subject to regulatory approvals and customary conditions. This strategic move is anticipated to enhance MannKind’s market reach and integrate scPharmaceuticals’ commercial capabilities into its existing infrastructure.

scPharmaceuticals Extends SmartDose Supply Agreement

On August 20, 2025, scPharmaceuticals Inc. amended its supply agreement with West Pharmaceutical Services, Inc. for the SmartDose® drug delivery system, extending the agreement’s term until December 31, 2027. The amendment outlines the company’s financial responsibilities upon termination, impacting its operational commitments and strategic partnerships in the drug delivery market.

scPharmaceuticals Holds Annual Stockholders Meeting June 2025

On June 3, 2025, scPharmaceuticals Inc. held its Annual Meeting of Stockholders, with 35,156,523 shares represented, accounting for approximately 69.91% of the company’s outstanding common stock. During the meeting, William T. Abraham, M.D., Mette Kirstine Agger, and Minnie Baylor-Henry were elected as Class II Directors, and the appointment of RSM US LLP as the independent registered public accounting firm was ratified. Additionally, the compensation of the company’s named executive officers was approved on an advisory basis.